Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world

Vodicka, P; Benesova, K; Janikova, A; Prochazka, V; Belada, D; Mocikova, H; Steinerova, K; Duras, J; Karban, J; Hanackova, V; Sykorova, A; Obr, A; Trneny, M

Trneny, M (通讯作者)，Charles Univ Prague, Dept Med 1, U Nemocnice 2, Prague 12808, Czech Republic.;Trneny, M (通讯作者)，Gen Univ Hosp, U Nemocnice 2, Prague 12808, Czech Republic.

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022; 109 (2): 162

Abstract

Objectives Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/re......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索